Navigation Links
Most Leukemia Patients Recover From 'Chemo Brain' After Transplant: Study
Date:5/6/2011

FRIDAY, May 6 (HealthDay News) -- A decline in memory and fine-motor skills is common among patients who undergo a bone marrow or stem cell transplant to treat leukemia or lymphoma, but most patients return to normal within five years, according to a new study.

Previous research has shown that the chemotherapy drugs these patients take before transplantation and medicines they take to prevent rejection of the transplanted cells can affect memory and motor skills. This study looked at how long it takes them to recover from those problems, often referred to as "chemo brain."

The study included 92 patients with chronic myeloid leukemia, acute leukemia, lymphoma or myelodysplastic syndrome, in which the bone marrow does not function normally. The patients had received an allogeneic (cells donated by another person) bone marrow or stem cell transplant.

After treatment, the patients' memory and motor skills were assessed. Most patients showed substantial improvement in neurocognitive function between one and five years after their transplant.

But deficits, described as mostly mild, persisted for five years in nearly 42 percent of the patients, a finding that surprised the researchers at the Fred Hutchinson Cancer Research Center in Seattle.

"We really thought the rates would be lower," study leader Karen Syrjala, director of Biobehavioral Sciences, said in a Hutchinson news release. "We were thrilled to see that people recovered substantially, but we also were surprised that so many people did continue to have measurable deficits in some areas even after five years."

Further research is needed to identify the reasons for these persistent deficits, she added.

The study was published May 2 online in the Journal of Clinical Oncology.

More information

The U.S. National Heart, Lung, and Blood Institute has more about bone marrow and stem cell transplant.

-- Robert Preidt

SOURCE: Fred Hutchinson Cancer Research Center, news release, May 3, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Agent selectively targets malignant B cells in chronic leukemia, study shows
2. Possible new approach to treating deadly leukemia in babies
3. New drug shows potential for treatment-resistant leukemia
4. ASH partners with AMEH and National Cancer Institute to improve diagnosis of leukemia in Mexico
5. Tracking down the origin of leukemia relapse
6. New approach to leukemia chemotherapy -- is a cure in sight?
7. UCSF researchers identify promising new treatment for childhood leukemia
8. Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib
9. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
10. Less Is More With Acute Myeloid Leukemia Drug
11. When leukemia returns, gene that mediates response to key drug often mutated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... this installment is bolstered by inspiring human interest stories, courtesy of leaders in ... trends and tech within the industry, from leading advocates and associations—namely Jones & ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... to support the company’s continued investment and strategic growth plans in the Asia ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior ... executive officer, today. In his new role, Marziani will lead the company,s business development ... professionals to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... -- Open Access Journal Focusing on ... Elsevier , a world-leading provider of scientific, technical ... launch of Clinical Neurophysiology Practice ... clinical practice issues in clinical neurophysiology. The journal will ... and didactic reviews. It is an official journal of ...
Breaking Medicine Technology: